Sarepta therapeutics announces results from part 2 of the embark study demonstrating sustained benefits and disease stabilization in ambulatory individuals with duchenne muscular dystrophy following treatment with elevidys

Cambridge, mass.--(business wire)--sarepta therapeutics, inc. (nasdaq: srpt), the leader in precision genetic medicine for rare diseases, today announced positive topline results from part 2 of embark (study srp-9001-301), a global, randomized, double-blind, placebo-controlled, phase 3 clinical study of elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with duchenne muscular dystrophy. crossover-treated patients, those who received a placebo in part 1 and.
SRPT Ratings Summary
SRPT Quant Ranking